SafeHeal SAS, together with its U.S. subsidiary SafeHeal Inc., designs and develops Colovac, a flexible endoluminal bypass sheath intended to shield the anastomotic site from fecal matter following colorectal surgery. The device remains in place for roughly 10 days and is later removed endoscopically, sparing patients a second surgical intervention and the lifestyle burdens of an ostomy bag. Colovac is currently limited to investigational use in the United States under an IDE study, while commercialization efforts are focused on the European Union. The newly raised capital will accelerate the U.S. pivotal IDE trial and fund EU commercial launch preparations. SafeHeal’s Series C round was initially €35 million and has now been extended, demonstrating strong investor interest. Although the company has not disclosed revenue or user metrics, its financing momentum underscores market confidence in the potential clinical and economic benefits of Colovac.

Total raised

$103M

Funding rounds

4

Latest round

Series C

Latest activity

Sep 2025